Skip to main content
IN THE KNOW

Resources. Press releases.

Client news
Health tech is trying to help people manage their diabetes. But is it enough?
The missing piece of coaching and personalized decision support.
READ MORE
Client news
The surprising impact of gene therapies.
If you think forecasting drug spend is difficult today, just wait.
READ MORE
Client news
Next generation Rx portal.
At MedImpact, we’re committed to making it even easier for members to manage their medications and related costs. That’s why we’re excited to share new features included in our Rx portal and mobile app.
READ MORE
Client news
MedImpact in American Health and Drug Benefits
Karen Geary explores how an individual’s genetic makeup can impact how they will react to certain medications, and how we can help make prescribing safer and more effective.
READ MORE
Client news
MedImpact leverages advanced technology and network solutions to improve member experience and reduce costs for our pharmacy partners.
The U.S. spends more per capita on healthcare than any other country in the world, but it has a high prevalence of diabetes, worse cardiovascular outcomes and lower life expectancy compared to other high-income countries.1 U.S. healthcare costs reached $3.6 trillion in 2018 and spending is anticipated to soar to nearly $6 trillion by 2027.2 However, the U.S. ranks poorly in health system performance.3
READ MORE
Client news
NY Attorney General recognizes MedImpact for assisting in multimillion dollar medicaid FWA investigation.
Fraud, waste, and abuse (FWA) is a national crisis that costs our healthcare system at least $200 billion every year. Even worse, research suggests that only a mere 5% of these losses are recovered.1
READ MORE
Client news
The hazards of auto-refills.
MedImpact helps reduce waste and oversupply with flexible auto-refill strategies.
READ MORE
Client news
Annual drug trend report looks at Medicare brand and generic drug trends.
Breaking news of the White House’s consideration of a sweeping executive order that could cut prices on brand-name prescription drugs sold to Medicare and other government programs continues to top this week’s healthcare headlines.
READ MORE
Client news
Investigating top diabetes trends by lines of business.
Diabetes spending will continue to increase as new pipeline agents like oral semaglutide enter the market. For now, insulin still dominates the diabetes therapeutic class, accounting for 49% of market share. Newer generation, non-insulin products, like DPP4, SGLT2 or GLP-1s, or combinations that contain them, now make up a combined 50% of market share.
READ MORE
We are the PBM that puts clients and consumers first. Always. Ready for a change?